Clinical Trial Update: An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis [Phase 4]

View source ↗

Summary

Phase 4 open-label study in postmenopausal women with estrogen receptor–positive locally advanced or metastatic breast cancer evaluating everolimus with exemest…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Advanced Breast Cancer

Drugs mentioned

• Everolimus (RAD001) (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Oestrogen Receptor Positive Advanced Breast Cancer | Phase 4 | Status: COMPLETED | Results posted: 2019-04-01